317 related articles for article (PubMed ID: 33805359)
1. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
3. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
[TBL] [Abstract][Full Text] [Related]
5. Hippo/YAP pathway for targeted therapy.
Felley-Bosco E; Stahel R
Transl Lung Cancer Res; 2014 Apr; 3(2):75-83. PubMed ID: 25806284
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
[TBL] [Abstract][Full Text] [Related]
7. Drug development against the hippo pathway in mesothelioma.
Woodard GA; Yang YL; You L; Jablons DM
Transl Lung Cancer Res; 2017 Jun; 6(3):335-342. PubMed ID: 28713678
[TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
[TBL] [Abstract][Full Text] [Related]
9. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Hsu PC; Yang CT; Jablons DM; You L
Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
[TBL] [Abstract][Full Text] [Related]
10. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
12. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
Mizuno T; Murakami H; Fujii M; Ishiguro F; Tanaka I; Kondo Y; Akatsuka S; Toyokuni S; Yokoi K; Osada H; Sekido Y
Oncogene; 2012 Dec; 31(49):5117-22. PubMed ID: 22286761
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas.
Oh JE; Ohta T; Satomi K; Foll M; Durand G; McKay J; Le Calvez-Kelm F; Mittelbronn M; Brokinkel B; Paulus W; Ohgaki H
J Neuropathol Exp Neurol; 2015 Oct; 74(10):952-9. PubMed ID: 26360373
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
[TBL] [Abstract][Full Text] [Related]
15. Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.
Pulito C; Korita E; Sacconi A; Valerio M; Casadei L; Lo Sardo F; Mori F; Ferraiuolo M; Grasso G; Maidecchi A; Lucci J; Sudol M; Muti P; Blandino G; Strano S
J Exp Clin Cancer Res; 2019 Aug; 38(1):349. PubMed ID: 31399037
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
Papavassiliou KA; Sofianidi AA; Papavassiliou AG
J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
[TBL] [Abstract][Full Text] [Related]
17. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
19. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.
Yang H; Xu D; Yang Z; Yao F; Zhao H; Schmid RA; Peng RW
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
